Ladang, Aurélie http://orcid.org/0000-0002-5316-3108
Kovacs, Stéphanie
Lengelé, Laetitia
Locquet, Médéa
Beaudart, Charlotte
Reginster, Jean-Yves
Bruyère, Olivier
Cavalier, Etienne
Article History
Received: 13 June 2023
Accepted: 27 July 2023
First Online: 15 August 2023
Declarations
:
: C. Beaudart reports to be a shareholder of SARQOL SRL, a spin-off of the University of Liege. O. Bruyere reports grants or fees from AMGEN, APTISSEN, BIOPHYTIS, IBSA, MEDA, SANOFI, SERVIER, SMB, THERAMEX and UCB outside the submitted work. He is also a shareholder of SARQOL SRL, a spin-off of the University of Liege. J-Y. Reginster reports consulting fees or paid advisory boards (IBSA-GENEVRIER, MYLAN, RADIUS HEALTH, PIERRE FABRE, ECHOLIGHT, TEVA), lecture fees when speaking at the invitation of sponsor (IBSA-GENEVRIER, MYLAN, CNIEL, DAIRY RESEARCH COUNCIL (DRC), TEVA), grant Support from Industry (All through Institution) (IBSA-GENEVRIER, MYLAN, CNIEL, RADIUS HEALTH). He is also a shareholder of SARQOL SRL, a spin-off of the University of Liege as well as the CARES SRL, former spin-off of the University of Liège. Other authors reported no conflict of interest in relation to this work.
: The SarcoPhage study was approved by the Ethical Committee of the CHU de Liège (2012/277).
: Written and signed informed consent was obtained from all individual participants included in this study.